in this issue
Regions :: North America
Novartis to acquire biotech company CoStim Pharmaceuticals
2:35 AM MST | February 17, 2014 | Natasha Alperowicz
Novartis announced today that it is buying CoStim Pharmaceuticals (Cambridge, MA), a privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer. The acquisition will broaden Novartis’s cancer immunotherapy research program, the company says. Financial terms were not disclosed. With this acquisition Novartis, already leading in cancer immunotherapy, with investigative chimeric antigen receptor (CAR) technology being developed in collaboration with the University of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee